Clinical trials
1 active trial in Germany
Recruiting, about to start, or running now.
- Adipositas Care & Health Therapy NCT04768127
Updated
Reviewed by Vidhi Upadhyay
Germany Endoscopic Bariatric Therapies Market Industry Trends and Forecast to 2034: Segmented by (Procedure, Product, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$37.4 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $22.9 Mn | — | — |
| 2025 (base) | $25.3 Mn | +$2.4 Mn | — |
| 2026 (forecast) | $28.0 Mn | +$2.7 Mn | +10.6% |
| 2027 (forecast) | $31.0 Mn | +$3.0 Mn | +22.3% |
| 2028 (forecast) | $34.3 Mn | +$3.3 Mn | +35.3% |
| 2029 (forecast) | $37.9 Mn | +$3.6 Mn | +49.6% |
| 2030 (forecast) | $41.9 Mn | +$4.0 Mn | +65.5% |
| 2031 (forecast) | $46.3 Mn | +$4.4 Mn | +83% |
| 2032 (forecast) | $51.3 Mn | +$4.9 Mn | +102.4% |
| 2033 (forecast) | $56.7 Mn | +$5.4 Mn | +123.9% |
| 2034 (forecast) | $62.7 Mn | +$6.0 Mn | +147.6% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $25.3 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $62.7 Mn placeholder estimate |
| Growth (CAGR), 2025–2034 | 10.6% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Procedure, product and end user (see all) |
| Key players | Boston Scientific Corporation, Apollo Endosurgery, Fractyl Health, GI Dynamics, Olympus Corporation (see all) |
| Regulator in Germany | BfArMSource: Federal Institute for Drugs and Medical Devices (BfArM). Checked 14 Nov 2026. |
| Active clinical trials | 1 in GermanySource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Germany. Retrieved 12 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Endoscopic bariatric therapies are weight-loss procedures done through the mouth with a flexible scope, without cuts in the skin.
Key segments of the endoscopic Bariatric Therapies market include procedure (Endoscopic Sleeve Gastroplasty, Intragastric Balloon and Duodenal Mucosal Resurfacing) and product (Suturing Systems, Balloons and Liners).
Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the endoscopic Bariatric Therapies market. Wider insurance coverage and more doctors trained in obesity care are adding to demand.
Oral formulations, combination therapies and use in heart, kidney and liver disease open new growth paths for the endoscopic Bariatric Therapies market, especially in fast-growing emerging economies.
High treatment prices, limited reimbursement, supply shortages and side effects that lead some patients to stop treatment hold back the endoscopic Bariatric Therapies market. Long-term safety data and lifestyle support are still needed for many patients.
The endoscopic Bariatric Therapies market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Medical devices need CE marking under the EU Medical Device Regulation (MDR); in Germany, BfArM assesses reports of incidents with them.[1] Most people have statutory health insurance; the Federal Joint Committee (G-BA) decides what it covers and rates the added benefit of new medicines.[2] ClinicalTrials.gov lists 1 study on Endoscopic Bariatric Therapies that is recruiting, active or about to start in Germany.[3] Obesity (adults): 20.6% of adults in 2024, the latest WHO figure for Germany.[4]
[1] Federal Institute for Drugs and Medical Devices (BfArM). Checked 14 Nov 2026.
[2] Federal Joint Committee (G-BA). Checked 14 Nov 2026.
[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Germany. Retrieved 12 Nov 2026.
[4] WHO Global Health Observatory, Obesity (adults) (% of adults). Retrieved 21 Nov 2026.
Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how endoscopic Bariatric Therapies products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in Germany.
What doctors and scientists are doing in Endoscopic Bariatric Therapies right now, from free public sources.
1 active trial in Germany
Recruiting, about to start, or running now.
20.6 % of adults
Obesity (adults), Germany, 2024 (WHO).
Compare every country on the Public Health DashboardSources: PubMed (US National Library of Medicine), ClinicalTrials.gov, WHO Global Health Observatory, World Bank. Fetched 21 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
[1] WHO Global Health Observatory, Obesity (adults) (% of adults). Retrieved 20 Nov 2026.
[2] World Bank Open Data, Health spending per person (US$ per person). Retrieved 20 Nov 2026.
[3] World Bank Open Data, Doctors (per 1,000 people). Retrieved 21 Nov 2026.
From our blog
Germany · 1 shared keyword
Germany · 1 shared keyword
Germany · 1 shared keyword
Germany
Germany
Germany
Pharmaceuticals · Germany
Pharmaceuticals · Germany
Healthcare Services · Germany
Digital Health · Germany
Pharmaceuticals · Germany
Pharmaceuticals · Germany